|
KMID : 0605720090150020199
|
|
Journal of the Korean Society of Biological Therapies in Psychiatry
2009 Volume.15 No. 2 p.199 ~ p.207
|
|
|
The Comparison of Efficacy and Safety between Aripiprazole and Haloperidol in the Treatment of Chronic Schizophrenia and Schizoaffective Disorder: Results from a 16-Week Clinical Study
|
|
Seo Young-Ik
Kim Jeong-Gee
Jang Og-Jin
|
|
|
Abstract
|
|
|
Objectives: The authors compared the efficacy and safety between aripiprazole and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Methods: This study was conducted in December, 2004 through April, 2007. We selected the subjects who were admitted to psychiatric clinic due to chronic schizophrenia or schizoaffective disorder as defined by DSM-Ⅳ criteria. The assessment of clinical symptoms was evaluated with PANSS before taking the drugs and every two weeks afterwards. The standard laboratory tests were also performed. The prolactin level was evaluated in every 4 weeks
Results: Total of 72 subjects were assigned either aripiprazole(N=33) or haloperidol(N=39) according to the admission order. There were no statistically significant differences on demographic variables. After 16-week study was completed, there were no statistically significant differences in positive, general and total score in PANSS except negative symptom. There were no significant differences among the variables related to metabolic syn￢drome except serum glucose and HDL cholesterol level between two groups. However, there was a significant difference in serum prolactin level.
Conclusion: In the end, aripiprazole was generally good choice of treatment with less side effects, better tolerability than haloperidol. One, aripiprazole showed more improvements in negative, general and total PANSS subscales with no statistical significances except negative PANSS score. The other, the variables related to the metabolic syndrome need a further evaluation. And the last, aripiprazole yields more favorable serum prolactin level than haloperidol.
|
|
|
KEYWORD
|
|
|
Chronic schizophrenia, Aripiprazole, Haloperidol
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|